About
Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India. It offers a portfolio of oncology drugs, oral drug delivery, and biogenerics. The company provides TrabiDHA for use in health food, baby food/formula, health supplement, and chicken and animal feed markets; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. The company was incorporated in 1990 and is based in Sangareddy, India.
Key Metrics
as of Sep 2026Market Cap21 Cr
P/E—
Div Yield0.00 %
Book Value₹1.11
52w High₹4.50
52w Low₹1.83
Face Value₹10.00
Quarterly Results
Rs. Crores · hover row for definition| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.08 | 0.08 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.10 |
| Expenses | 0.12 | 0.33 | 0.10 | 0.13 | 0.18 | 0.62 | 0.17 | 0.13 | 0.46 | 0.32 | 0.16 | 0.17 | 0.22 |
| Operating Profit | -0.06 | -0.28 | -0.05 | -0.08 | -0.13 | -0.54 | -0.09 | -0.07 | -0.41 | -0.27 | -0.11 | -0.12 | -0.12 |
| OPM % | -100.00 | -560.00 | -100.00 | -160.00 | -260.00 | -675.00 | -112.50 | -116.67 | -820.00 | -540.00 | -220.00 | -240.00 | -120.00 |
| Other Income | 0.00 | 0.15 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.04 | 0.65 | 0.05 | 0.04 | 0.04 | 0.04 |
| Depreciation | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Interest | 0.29 | 0.28 | 0.27 | 0.26 | 0.25 | 0.19 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 |
| Profit before tax | -0.39 | -0.46 | -0.37 | -0.39 | -0.43 | -0.71 | -0.09 | -0.07 | 0.20 | -0.27 | -0.12 | -0.13 | -0.13 |
| Tax % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | -0.39 | -0.46 | -0.37 | -0.39 | -0.43 | -0.71 | -0.09 | -0.07 | 0.20 | -0.27 | -0.12 | -0.13 | -0.13 |
| EPS in Rs | -0.05 | -0.06 | -0.05 | -0.05 | -0.06 | -0.09 | -0.01 | -0.01 | 0.03 | -0.04 | -0.02 | -0.02 | -0.02 |
Profit & Loss
Annual · Rs. Crores| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.21 | 0.26 | 0.23 | 0.06 | 0.09 | 0.17 | 0.00 | 0.07 | 0.12 | 0.28 | 0.18 | 0.30 |
| Expenses | 0.75 | 1.38 | 0.83 | 0.68 | 0.55 | 0.70 | 0.87 | 0.75 | 2.22 | 2.84 | 1.32 | 1.90 |
| Operating Profit | -0.54 | -1.12 | -0.60 | -0.62 | -0.46 | -0.53 | -0.87 | -0.68 | -2.10 | -2.56 | -1.14 | -1.60 |
| OPM % | -257.14 | -430.77 | -260.87 | -1,033.33 | -511.11 | -311.76 | — | -971.43 | -1,750.00 | -914.29 | -633.33 | -533.33 |
| Other Income | 0.15 | 0.78 | 0.18 | 0.18 | 0.21 | 0.27 | 0.18 | 2.04 | 7.37 | 0.66 | 0.17 | 0.01 |
| Interest | 1.06 | 0.24 | 0.14 | 0.62 | 0.23 | 0.27 | 0.38 | 0.26 | 1.03 | 0.43 | 0.07 | 0.36 |
| Depreciation | 0.20 | 0.09 | 0.09 | 4.95 | 9.92 | 9.91 | 9.90 | 9.89 | 9.89 | 17.53 | 20.50 | 17.18 |
| Profit before tax | -1.65 | -0.67 | -0.65 | -6.01 | -10.40 | -10.44 | -10.97 | -8.79 | -5.65 | -19.86 | -21.54 | -19.13 |
| Tax % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.98 | 0.00 | 0.00 | 0.00 |
| Net Profit | -1.65 | -0.68 | -0.66 | -6.01 | -10.40 | -10.43 | -10.96 | -8.79 | -6.44 | -19.86 | -21.54 | -19.14 |
| EPS in Rs | -0.22 | -0.09 | -0.09 | -0.79 | -1.37 | -1.38 | -1.45 | -1.16 | -0.85 | -2.62 | -2.84 | -2.53 |
| Dividend Payout % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance Sheet
Annual · Rs. Crores — latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 |
| Reserves | -67.39 | -65.74 | -65.06 | -64.40 | -58.39 | -53.53 | -43.10 | -32.13 | -23.34 | -16.90 | 98.67 | 115.62 |
| Borrowings | 17.14 | 14.52 | 14.00 | 13.11 | 12.01 | 11.33 | 10.33 | 9.14 | 9.84 | 16.01 | 15.28 | 14.43 |
| Other Liabilities | 118.14 | 119.54 | 117.62 | 117.87 | 117.71 | 123.31 | 123.75 | 123.77 | 124.28 | 123.18 | 123.27 | 137.95 |
| Total Liabilities | 143.66 | 144.09 | 142.33 | 142.35 | 147.10 | 156.88 | 166.75 | 176.55 | 186.55 | 198.06 | 312.99 | 343.77 |
| Fixed Assets | 9.63 | 7.96 | 6.36 | 6.45 | 11.40 | 21.32 | 31.20 | 41.10 | 50.97 | 61.16 | 140.95 | 163.40 |
| CWIP | 0.00 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 2.04 | 0.29 | 0.29 |
| Investments | 0.09 | 0.10 | 0.10 | 0.10 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 133.94 | 134.16 | 134.00 | 133.93 | 133.73 | 133.69 | 133.68 | 133.58 | 133.71 | 134.86 | 171.75 | 180.08 |
| Total Assets | 143.66 | 144.09 | 142.33 | 142.35 | 147.10 | 156.88 | 166.75 | 176.55 | 186.55 | 198.06 | 312.99 | 343.77 |
Cash Flows
Annual · Rs. Crores — latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -0.01 | 1.20 | 0.00 | 0.00 | 0.10 | 0.01 | 0.14 | -1.74 | -0.63 | 0.02 | 6.47 | 3.52 |
| Cash from Investing Activity | 0.15 | -1.70 | 0.00 | -0.01 | -0.10 | -0.03 | 0.00 | 1.74 | 3.05 | 0.00 | -6.47 | -4.57 |
| Cash from Financing Activity | -0.36 | 0.78 | 0.00 | 0.00 | 0.00 | 0.00 | -0.20 | 0.00 | -2.37 | 0.00 | 0.00 | 1.03 |
| Net Cash Flow | -0.22 | 0.28 | 0.00 | -0.01 | 0.00 | -0.01 | -0.06 | 0.00 | 0.05 | 0.02 | 0.00 | -0.02 |
| Free Cash Flow | 0.14 | -0.50 | 0.00 | 0.00 | 0.10 | -0.02 | 0.14 | -0.01 | 2.74 | 0.02 | 0.00 | -1.05 |
| CFO/OP % | 2.00 | -107.00 | 0.00 | 0.00 | -22.00 | -2.00 | -16.00 | 256.00 | 30.00 | -1.00 | -568.00 | -220.00 |
Ratios
Annual · Days / % — latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 17.38 | 14.04 | 15.87 | 60.83 | 40.56 | 21.47 | — | 52.14 | 30.42 | 13.04 | 3,325.56 | 19,953.33 |
| Inventory Days | — | — | — | 156.43 | — | 121.67 | 1,460.00 | 365.00 | 365.00 | — | — | — |
| Days Payable | — | — | — | 1,199.29 | — | 1,460.00 | 13,870.00 | 3,528.33 | 5,018.75 | — | — | — |
| Cash Conversion Cycle | 17.38 | 14.04 | 15.87 | -982.02 | 40.56 | -1,316.86 | — | -3,111.19 | -4,623.33 | 13.04 | 3,325.56 | 19,953.33 |
| Working Capital Days | -21,361.19 | -16,509.23 | -15,933.04 | -57,365.83 | -34,593.89 | -29,092.65 | — | -62,519.29 | -39,967.50 | -14,339.29 | -16,019.44 | -8,528.83 |
| ROCE % | -2.36 | -1.75 | -2.07 | -20.01 | -32.31 | -26.56 | -22.11 | -17.91 | -10.97 | -14.69 | -10.86 | -8.83 |
Corporate Actions
No corporate actions recorded.